UroGen Pharma (URGN) Operating Expenses (2017 - 2026)

UroGen Pharma (URGN) has reported Operating Expenses for 10 consecutive years, with $67.1 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Expenses rose 22.33% year-over-year to $67.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $234.4 million (up 23.17% YoY) and the FY2025 annual result came in at $222.2 million, up 24.62% from the prior year.
• Operating Expenses climbed to $67.1 million in Q1 2026 per URGN's latest filing, from $53.7 million in the prior quarter.
• Over the last five years, Operating Expenses for URGN reached as high as $67.1 million in Q1 2026 and fell as low as $32.0 million in Q3 2023.
• A 5-year average of $43.7 million and a median of $40.3 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses dropped 4.12% — and 2024, when it jumped 38.77%.
• Year by year, Operating Expenses stood at $36.1 million in 2022, then fell by 0.71% to $35.9 million in 2023, then soared by 38.77% to $49.8 million in 2024, then gained by 7.86% to $53.7 million in 2025, then grew by 25.01% to $67.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $67.1 million, $53.7 million, and $51.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.